Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293286 | 0.94 | MEN1 (0.53) | CA2HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL3127163 | 0.92 | MAPT (0.55) | CA2MAPTMEN1KMT2ARXFP1 | |
| SCHEMBL6117904 | 0.92 | MAPT (0.55) | CA2MAPTMEN1KMT2ARXFP1 | |
| SCHEMBL14399650 | 0.92 | MAPT (0.55) | CA2MAPTMEN1KMT2ARXFP1 | |
| SCHEMBL9809202 | 0.92 | MAPT (0.55) | CA2MAPTMEN1KMT2ARXFP1 | |
| SCHEMBL3139656 | 0.92 | MAPT (0.55) | CA2MAPTMEN1KMT2ARXFP1 | |
| SCHEMBL3139639 | 0.92 | MAPT (0.55) | CA2MAPTMEN1KMT2ARXFP1 | |
| SCHEMBL3141008 | 0.92 | MAPT (0.55) | CA2MAPTMEN1KMT2ARXFP1 | |
| SCHEMBL2317361 | 0.92 | MAPT (0.55) | CA2MAPTMEN1KMT2ARXFP1 | |
| SCHEMBL3144325 | 0.92 | MAPT (0.55) | CA2MAPTMEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024128570-A1 | METHOD FOR PRODUCING CRYSTALLINE FIBER USING CARBOXYLIC ACID, SULFONIC ACID, PHOSPHORIC ACID, OR ACID SALT DERIVATIVE THEREOF | (주)비에이에너지 | 2024-06-20 | — | — | WO | claimed |
| US-8383628-B2 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-02-26 | — | — | US | claimed |
| EP-1651606-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-10-24 | — | — | EP | claimed |
| EP-1651605-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | claimed |
| US-20100305138-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-12-02 | — | — | US | claimed |
| US-20100048584-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-02-25 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| JP-2007500716-A | — | — | 2007-01-18 | — | — | JP | claimed |
| JP-2007500719-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-12-28 | — | — | US | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1651606-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| EP-1651605-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011654-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| WO-2005011656-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| US-20250020997-A1 | PHOTORESIST COMPOSITIONS AND METHODS OF MANUFACTURING INTEGRATED CIRCUIT DEVICES USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-01-16 | — | — | US | disclosed |
| CN-119241931-A | Biodegradable butyronitrile glove and preparation method thereof | 江苏理工学院 | 2025-01-03 | — | — | CN | disclosed |
| US-4294986-A | Novel para-phenylalkoxy phenylurea and thiourea compounds and herbicidal use thereof | AMERICAN CYANAMID CO. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4289903-A | PREEMERGENCE AND POSTEMERGENCE | AMERICAN CYANAMID COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048584-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | PRMT9, SNRPD3, SCD | CA2 4733/4885HDAC1 2658/4885HDAC8 3599/4885 |
| US-20100305138-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | PRMT9, SNRPD3, PRDX5 | CA2 4733/4885HDAC1 2758/4885HDAC8 3691/4885 |
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | PRMT9, SNRPD3, PRDX5 | CA2 4733/4885HDAC1 2758/4885HDAC8 3691/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | CA2 4040/4885HDAC1 1503/4885HDAC8 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.